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1  | INTRODUC TION
The outpatient management of decompensated cirrhosis is com-
plex and multifaceted.1 For ascites alone, high-quality care depends 
on the adherence to dietary sodium restriction, weight tracking, 
timely and careful diuretic adjustments, electrolyte and renal func-
tion monitoring, and the coordination of large volume paracenteses 
when needed.2,3 When outpatient monitoring fails, the risk of an 
otherwise preventable admission increases, carrying with it the risk 
of readmission.4,5 Hospitalization, in turn, diminishes health-related 
quality of life and places an exceptional burden on patients and their 
caregivers in addition to healthcare costs and risks of hospital-ac-
quired infections.6,7 Office-based visits are essential but may be too 
infrequent to coordinate care and capture decompensating events at 
a stage where successful intervention can prevent hospitalization.8 
For this reason, interest in the use of telehealth as an adjunct to out-
patient follow-up is on the rise.
Multiple platforms for telehealth have been evaluated for per-
sons with cirrhosis. In a prospective trial from our centre, automated 
interactive voice calls were able to effectively identify individuals 
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Abstract
Background and Aims: The development of cirrhosis-related smartphone applica-
tions for remote monitoring is increasing. Whether patients with cirrhosis will wel-
come such new technology, however, is uncertain.
Methods: We prospectively enrolled patients with cirrhosis (N = 102) to determine 
predictors of acceptance and utilization of a smartphone application for cirrhosis 
management using a 12-item Technology Acceptance Model (TAM) survey. Patients 
were then shown the EncephalApp© and evaluated for their willingness to download 
and use the application.
Results: Patients had a median age of 61.3 years and 63.7% had a history of he-
patic decompensation. Intention to use the hypothetical application was associated 
with perceived usefulness (β: 0.4, 95% CI: 0.3-0.5) and the presence of a caregiver 
(β: 1.1, 95% CI: 0.2-2.0). Of the eligible participants, 71% agreed to download the 
EncephalApp© and the decision was influenced by computer anxiety, behavioural 
intent, caregiver presence and disease state factors. Actual usage was 32% and not 
associated with baseline characteristics or the technology acceptance model.
Conclusions: Patient acceptance of smartphone applications for the management of 
cirrhosis is high and related to their attitudes towards technology and the presence 
of a caregiver. However, usage was low. Future research must employ behavioural 
interventions to optimize uptake and utilization of remote monitoring technology.
K E Y W O R D S
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most at risk for hospitalization based on symptoms such as weakness 
and rapid weight gain.9 Elsewhere, live telephone-based communica-
tions between healthcare workers and patients in the post-discharge 
period were associated with improved 6-month survival in cirrho-
sis.10 Naturally, as the vast majority of people now own smartphones, 
there has been a shift towards the development of smartphone appli-
cations to provide a more continuous and easily expandable method 
of outpatient disease monitoring.11-13 As illustrated by Ganapathy 
et al, a smartphone application provided to persons with cirrhosis 
and their caregivers that was capable of monitoring psychometric 
performance was able to identify and alert the care team to changes 
in a patient's cognition, facilitating early intervention.14 Nonetheless, 
there are currently minimal data on patient acceptance of smart-
phone applications to track their disease. Knowledge of factors asso-
ciated with a patient's acceptance and use of technology to manage 
their liver disease is important in guiding the development of these 
novel tools.15 In the current study, we measured overall technology 
acceptance in a cohort of patients with cirrhosis using a modified 




Using convenience sampling, all patients age >18 years with cir-
rhosis, presenting for an outpatient hepatology or liver transplant 
clinic visit at our hospital between 10/2019 and 1/2020, were eli-
gible for inclusion in the study. No patients were recruited during 
the last week of 11/2019 or at all during 12/2019 to avoid participa-
tion during the holidays. The diagnosis of cirrhosis must have been 
documented in a previous clinic encounter by the patient's hepa-
tologist and supported by clinical, laboratory, imaging, elastography 
or biopsy data. Manual chart review was also performed to deter-
mine cirrhosis stage (compensated or decompensated), history of 
decompensating events (variceal bleeding, hepatic encephalopathy, 
ascites, hepatorenal syndrome, hepatic hydrothorax and sponta-
neous bacterial peritonitis), disease severity (Model for End-Stage 
Liver Disease Sodium, MELD-Na) and cirrhosis-related medications. 
Additionally, we collected information regarding a patient's zip code 
(to determine median household income by zip code), the presence 
of an activated patient portal, and the presence and type of smart-
phone they owned. Patients were excluded if they had a history of 
a liver transplantation, were not English speaking or could not read 
English, or had significant mental deficits at the time of enrolment 
(dementia, West Haven grade 2 or higher hepatic encephalopathy).
2.2 | Survey design and administration
The technology acceptance model (TAM) is a theoretical frame-
work that seeks to explain technology acceptance and use.16 TAM 
assesses how a potential user perceives the usefulness (perceived 
usefulness, PU) and ease of use (perceived ease of use, PEOU) of 
a new technology, and how those factors impact that technol-
ogy's uptake and use.15,16 Combined, perceived usefulness and 
perceived ease of use account for 40% of an individual's inten-
tion to use (behavioural intent) and actual usage of a novel tech-
nology.17 One important contributor to perceived ease of use is 
emotional in nature and termed Computer Anxiety (CANX), or the 
extent to which one is fearful or averse to technology.18 While 
further research has expanded on several additional key factors 
that influence both perceived usefulness and perceived ease of 
use, the TAM model in the current study included items related to 
computer anxiety, perceived ease of use, perceived usefulness and 
behavioural intent.15
Prior to administering the survey, patients were asked to read 
a short prompt about a hypothetical interactive phone application 
(‘Cirrhosis Health Application’) designed to help in cirrhosis care 
(Figure S1). The statement described the potential utility of the 
phone application in the management of ascites, hepatic enceph-
alopathy, medication adherence and overall disease state, similar 
to a previously studied mobile application (the Patient Buddy ap-
plication).14 We then administered a modified 12-item TAM survey 
(Likert scale from 1 ‘definitely disagree’ to 7 ‘definitely agree’), with 
higher scores indicating higher technology acceptance (Figure S2). 
It is conventional to adapt the questions of the TAM survey to re-
flect the specific technology under evaluation.19,20 To ensure face 
validity while modifying the questions to focus on the Cirrhosis 
Health Application, we tested and revised the modified questions 
with physicians and health services researchers not associated 
with the study. Computer anxiety questions were negatively scaled 
so that higher scores indicated less comfort with technology. We 
also assessed for the presence of an in-home informal caregiver, 
defined here as a family member or friend who could, if needed, 
assist in basic activities of daily living. As a freely available compre-
hensive cirrhosis-related health application does not yet exist, we 
used as a test-case the canonical cirrhosis app: the EncephalApp 
Key points
• The care of patients with cirrhosis is complex and re-
quires frequent monitoring.
• There is increasing interest in augmenting ambulatory 
monitoring through the use of smartphone applications.
• However, an understanding of factors associated with 
patient acceptance of these technologies is lacking.
• Here, we show that principles of the technology ac-
ceptance model (perceived usefulness, perceived ease 
of use and computer anxiety) as well as patient baseline 
characteristics can easily identify potential adopters of 
a cirrhosis-related smartphone application.
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Stroop Test©, which is a free, well studied and clinically useful 
point-of-care smartphone application designed and able to detect 
no, covert and overt hepatic encephalopathy.21-25 Following survey 
completion, patients owning a smartphone and without red-green 
colour blindness (an exclusion criterion for the EncephalApp©) 
were told the purpose of and then actively watched a member of 
the research team (JL) perform a short run of the EncephalApp© 
to ensure understanding (Figure 1). Participants were then asked 
if they would be agreeable to download the application onto their 
own smartphone with the intention of using it once or twice be-
tween 7 and 15 days after installation. Agreeable participants 
then downloaded the application with the help of a member of 
the research team (JL). Settings were adjusted to make the testing 
non-diagnostic as we could not control the environment in which 
the application would be completed and the results interpreted. 
The study email address was entered into the application so that 
after a participant completed the application, the study team 
would be alerted via email. After 18 days post-enrolment, we at-
tempted to contact those who downloaded but did not complete 
the EncephalApp© to assess for any barriers that prevented use of 
the application. The study received approval from the University 
of Michigan Institutional Review Board and all study participants 
provided written consent.
2.3 | Statistical analysis
Descriptive data were presented as number (percent) for categori-
cal data and mean (standard deviation, SD) or median (interquartile 
range, IQR) for continuous data. We sought to characterize factors 
(demographic and clinical characteristics, perceived usefulness, 
perceived ease of use, computer anxiety) associated with higher 
behavioural intent (the statistical mean of questions 9 and 10) to 
use the hypothetical Cirrhosis Health Application. Correlations 
between TAM constructs were analysed using Pearson's correla-
tion coefficient. Linear regression was used to identify predictors 
of behavioural intent and logistic regression was used to determine 
if demographic and clinical characteristics as well as TAM con-
structs could explain a patient's decision to download and use the 
EncephalApp©. These analyses were performed initially using uni-
variable logistic regression. Given multiple predictor variables and 
multicollinearity, penalized regression using Lasso regression was 
performed for variable selection.26 Non-zeroed variables from the 
Lasso regression were then analysed in a multivariable logistic re-
gression model. Significance was determined using 95% confidence 
intervals (95% CI), and P < .05. We hypothesized that behavioural 
intent would increase by 20% in the presence of decompensated cir-
rhosis. Using mean and standard deviation behavioural intent values 
F I G U R E  1   Flow diagram of patient acceptance and use of the EncephalApp©
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from Venkatesh et al15 and power of 0.8, we required a sample size 
of at least 68 patients. Data were collected using REDCap. We per-
formed the statistical analysis using RStudio.27
3  | RESULTS
A total of 140 patients were approached for inclusion in the study 
and a total of 102 (73%) patients agreed to complete the survey. 
Participants had a median age of 61.3 years, were predominantly 
white (90.2%) and 56.9% were men (Table 1). Cirrhosis was most 
commonly related to alcohol use disorder (37.3%) and non-alcoholic 
fatty liver disease (30.4%). A history of decompensation was pre-
sent in 63.7% of participants at the time of enrolment. A history of 
ascites and hepatic encephalopathy was present in 48 (47.1%) and 
40 (39.2%) patients, respectively. The median MELD-Na was 10. 
Smartphone ownership was 93.1%.
3.1 | Behavioural intent to use the hypothetical 
cirrhosis health app
Mean survey item scores for perceived usefulness, perceived ease 
of use and the absolute value of computer anxiety were between 
5 and 5.2 out of 7 (SD 1.2-1.8) (Table 2). Behavioural intent to use 
the hypothetical cirrhosis health application was significantly cor-
related with perceived usefulness (r = .77, 95% CI: 0.67-0.84), per-
ceived ease of use (r = .65, 95% CI: 0.52-0.75) and computer anxiety 
(r = −.54, 95% CI: −0.66 to −0.38). Combined, these variables ex-
plained 61% of the variance in behavioural intent to use the Cirrhosis 
Health Application (adjusted R2 = .61).
Univariable linear regression for predictors of behavioural intent 
is illustrated in Table 3. Variable selection using Lasso regression re-
vealed age, median household income by zip-code, perceived use-
fulness, perceived ease of use, computer anxiety, the presence of 
a caregiver and the presence of an ascites medication as important 
predictors of behavioural intent. Together, these variables explained 
64% of the variance in behavioural intent (adjusted R2 = .64). On 
multiple logistic regression, significant predictors of behavioural 
intent included perceived usefulness (β = 0.4, 95% CI: 0.3-0.5) and 
caregiver presence (β = 1.1, 95% CI: 0.2-2.0).
Analysis of characteristics associated with the antecedents of 
behavioural intent (perceived usefulness, perceived ease of use and 
computer anxiety) revealed that the presence of a caregiver was as-
sociated with higher perceived usefulness (β = 2.7, 95% CI: 0.5-4.8), 
perceived ease of use (β = 3.8, 95% CI: 1.8-5.9) and lower computer 
anxiety (β = −2.5, 95% CI: −4.0 to −0.9). For every 1-year increase 
in age, there was both a 0.09 increase in computer anxiety (95% CI: 
0.04-0.1) and decrease in perceived ease of use (95% CI: −0.2 to 
−0.01). Neither MELD-Na nor median household income by zip code 
was correlated with perceived usefulness, perceived ease of use or 
computer anxiety.
3.2 | Factors associated with agreement to 
download the EncephalApp©
Of the 102 participants who completed the TAM survey, 11 (10.8%) 
were excluded (1 for red/green colour blindness, 7 due to not own-
ing a smartphone and 3 who were unable to continue due to time 
TA B L E  1   Baseline characteristics
Demographics N = 102 (%)





Black/African American 9 (8.8)
Other/unknown 1 (1.0)
Median household income by zip code (USD) 58 680
Cirrhosis aetiologiesa 
Non-alcoholic fatty liver disease 31 (30.4)
Alcohol 38 (37.3)
Hepatitis C virus 18 (17.6)




Hepatic encephalopathy 40 (39.2)
Variceal haemorrhage 14 (13.7)
Spontaneous bacterial peritonitis 11 (10.8)
Hepatic hydrothorax 8 (7.8)
Hepatorenal syndrome 5 (4.9)
None 36 (36.3)
Median MELD-Na (IQR) 10.0 (8.0-15.8)
Active patient portal 71 (69.6)
Caregiver 76 (74.5)
Abbreviations: USD, United States dollars; MELD-Na, model for end-
stage liver disease sodium; IQR, interquartile range.
aMay have > 1 aetiology or complication of cirrhosis 






Perceived usefulness (PU) 1, 3, 5, 7 20.8 (5.0) 5.2 (1.2)
Perceived ease of use 
(PEOU)
2, 4, 6, 8 20.0 (4.9) 5.0 (1.2)
PU + PEOU 40.7 (9.1)
Computer anxiety 11, 12 −10.2 (3.6) −5.1 (1.8)
Behavioural intent 9, 10 10.2 (3.1) 5.1 (1.6)
Abbreviations: TAM, technology acceptance model; SD, standard 
deviation.
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constraints). The remaining 91 (89.2%) patients were shown the 
EncephalApp© and 65 (71.4%) patients expressed willingness to 
download the EncephalApp©. On univariable logistic regression, 
agreement to download the application was increased in the pres-
ence of an informal caregiver (OR: 4.03, 95% CI: 1.44-11.29), a his-
tory of hepatic decompensation (OR: 3.07, 95% CI: 1.20-7.85), a 
history of ascites (OR: 3.44, 95% CI: 1.22-9.67) or the presence of 
any cirrhosis-related medication (OR: 2.56, 95% CI: 1.01-6.52), in 
particular, the presence of an ascites-related medication (OR: 3.04, 
95% CI: 1.08-8.54) (Table 4). Additionally, perceived usefulness (OR: 
1.07, 95% CI: 1.05-1.30), perceived ease of use (OR: 1.19, 95% CI: 
1.06-1.33), computer anxiety (OR: 0.75, 95% CI: 0.64-0.87) and be-
havioural intent (OR: 1.35, 95% CI: 1.12-1.62) scores were all signifi-
cantly associated with agreement to download the EncephalApp©. 
Variable selection after Lasso regression identified computer anxi-
ety, behavioural intent, presence of a caregiver, presence of an as-
cites medication, hepatic decompensation and a history of ascites 
as important model covariates. Computer anxiety was the only 
variable significantly associated with willingness to download the 
EncephalApp© on multivariable logistic regression (OR: 0.78, 95% 
CI: 0.65-0.93).
3.3 | Use of the EncephalApp© smartphone 
application
Overall, 21 (32.3%) of 65 patients who expressed willingness to 
download the application were not able to successfully do so. Six 
patients were found to not have their phone with them, 4 were 
not able to access the Internet at the time of enrolment, 9 did not 
know their smartphone application store log-in information and 2 
patients did not have enough storage on their device. Of the remain-
ing 44 (67.7%) patients who agreed to and successfully downloaded 
the EncephalApp©, we received email evidence of its use from 14 
(31.8%) patients on at least one occasion between day 7 and 15 after 
enrolment. Neither TAM constructs nor baseline characteristics 
could explain the likelihood of application usage (Table S1).
3.4 | Barriers to EncephalApp© use
We attempted to contact the 30 patients for whom we did not re-
ceive an application-generated email showing proof of application 
completion to assess for any barriers to the application's use. Four 
(13.3%) patients were hospitalized in the 16 days after they down-
loaded the application. Of the remaining 26 participants, we were 







β coefficient (95% CI)
Age (years) −0.06 (−0.1 to 
−0.02)
−0.02 (−0.05 to 0.01)
Sex (male) −0.7 (−1.9 to 0.6)
MELD-Na 0.04 (−0.1 to 0.2)
Median household 
income by zip code 
(USD)
0.07 (−0.2 to 0.4) −0.07 (−0.3 to 0.1)
Decompensated 0.4 (−0.8 to 1.7)
History of ascites 0.5 (−0.7 to 1.7)
History of hepatic 
encephalopathy
0.6 (−0.7 to 1.8)
No cirrhosis 
medication




0.8 (−0.4 to 2.1)
Ascites medication 0.7 (−0.5 to 2.0) 0.7 (−0.07 to 1.4)
Caregiver presence 2.6 (1.3-3.9) 1.1 (0.2-2.0)
Active portal account 1.6 (0.3-2.9)
Perceived usefulness 0.5 (0.4-0.6) 0.4 (0.3-0.5)
Perceived ease of use 0.4 (0.3-0.5) 0.06 (−0.06 to 0.2)
Computer anxiety −0.5 (−0.6 to 
−0.3)
−0.09 (−0.2 to 0.05)
Abbreviations: CI, confidence interval; MELD-Na, model for end-stage 
liver disease sodium; USD, United States dollars.
TA B L E  4   Analysis of factors associated with willingness to 
download the EncephalApp©
N = 91
Agreed to Download (N = 65)
Did not Agree to 





Age (years) 0.98 (0.95-1.02)
Sex (male) 0.69 (0.27-1.73)
Median household income by 
zip code (USD)
1.08 (0.84-1.38)
Perceived usefulness (PU) 1.17 (1.05-1.30)
Perceived ease of use (PEOU) 1.19 (1.06-1.33)
Computer anxiety (CANX) 0.75 (0.64-0.87) 0.78 (0.65-0.93)
Behavioural intent (BI) 1.35 (1.12-1.62) 1.11 (0.89-1.38)
MELD-Na 1.05 (0.96-1.15)
Caregiver presence 4.03 (1.44-11.29) 2.31 (0.68-7.83)
Active portal account 1.62 (0.61-4.34)
Decompensated 3.07 (1.20-7.85) 1.39 (0.30-6.38)
Ascites 3.44 (1.22-9.67) 1.56 (0.26-9.27)
Hepatic encephalopathy 2.69 (0.95-7.56)
Taking any cirrhosis-related 
medication
2.56 (1.01-6.52)





Abbreviations: CI, confidence interval; USD, United States dollars; 
MELD-Na, model for end-stage liver disease sodium.
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able to successfully contact 13 (50%) of them to assess for barriers 
to use of the application. Ten (76.9%) simply forgot to complete the 
application, 1 (7.7%) noted difficulty running the application and 2 
(15.4%) stated the application was indeed completed which also sug-
gested a technical issue occurred.
4  | DISCUSSION
Early identification of cirrhosis complications in the ambulatory set-
ting is necessary to improve the quality of care provided to patients 
with chronic liver disease. Mobile telehealth tools can be employed 
to enhance outpatient monitoring beyond what can be provided 
with traditional outpatient visits alone.13 However, a lack of un-
derstanding about the factors that would lead to technology use 
in this population would simply result in the creation of underused 
and financially expensive interventions.15,18,28 Our results show that 
those most likely to download a cirrhosis-related smartphone ap-
plication are readily identified using principles from the technology 
acceptance model (perceived usefulness, perceived ease of use and 
computer anxiety), the presence of cirrhosis complications and med-
ications, and the presence of an informal caregiver. Nonetheless, our 
results also highlight the barriers that must be overcome to achieve 
a meaningful level of usage. Even among patients who downloaded a 
mobile telehealth application in clinic, we observed low levels of af-
ter-visit engagement with the technology. Our data therefore show 
that even for patients who are comfortable with technology, no 
smartphone application-based monitoring programme can be suc-
cessfully deployed without additional coaching or behavioural inter-
ventions. This study offers several lessons to extend our knowledge 
of how patients with cirrhosis interact with technology.
4.1 | Acceptance of the hypothetical cirrhosis health 
application
We found that nearly 70% of patients perceived the hypothetical 
Cirrhosis Health Application as useful (mean perceived usefulness 
score of 5 or higher). This favourable result likely reflected two study 
design decisions that should serve as a guide for how future applica-
tions are designed and introduced to patients. First, the information 
provided about the application was simple, positive and meant to 
help patients easily identify if there was a function of the application 
that applied to their care. We did not assume patients understood 
the drivers of their complications as patient knowledge of cirrhosis-
related care and complications ranges from 25% to 53%.29,30 Second, 
the information provided likely highlighted to patients the potential 
future complications they could face; therefore, how the application 
could be of use in the future. Both of these design factors likely im-
proved the technology's relevance to the end-user and contributed 
to perceived usefulness.15
The fact that patients were unable to interact with either the 
hypothetical Cirrhosis Health Application or the EncephalApp© 
prior to answering the TAM survey questions was a strength of the 
study. When measured prior to an interaction with a new system, 
perceived ease of use values reflect a patient's general confidence 
in their use of technology rather than system-specific factors.31 
Therefore, our finding of high perceived ease of use leading to in-
creased behavioural intent to use the hypothetical Cirrhosis Health 
Application is generalizable, at least in our population, to other cir-
rhosis-related smartphone applications designed to monitor medica-
tion and dietary adherence, weight and psychometric changes.
4.2 | Antecedents of technology 
acceptance and adoption
In the current study, we expand the current understanding of tech-
nology acceptance and adoption in cirrhosis. The available literature 
has revealed promising results from studies employing tablets and 
mobile devices in cirrhosis care. For example, providing patients and 
caregivers with mobile devices with a pre-installed cirrhosis care 
application can potentially prevent hepatic encephalopathy-related 
readmissions.14 Bloom et al showed that administering Bluetooth-
enabled scales to patients with ascites resulted in successful (70%) 
transmission of weights during the study period.32 Lastly, in an 
observational study where tablets for telemonitoring (in-home 
monitoring of vital signs) were provided to post-liver transplanta-
tion patients, high use was associated with lower readmissions.33 
However, giving devices to everyone overlooks key adoption and 
use factors. Indeed, we found that patients who were very accept-
ing of technology actually demonstrated low rates of after-visit use. 
Moreover, administering a novel technology indiscriminately is not 
practical or economically sound on a large scale.
Care teams must understand important antecedents of be-
havioural intent when designing and implementing novel cirrho-
sis-related smartphone applications. These elements include how 
useful a patient perceives the technology, which includes easily 
identifiable disease-state factors, as well as the patient's self-re-
ported comfort with technology and the presence of a caregiver 
(Figure S3). All of these characteristics can be readily gathered with 
minimal effort during a clinic encounter. Combined, these factors ex-
plain nearly two-thirds of a patient's intention to use a cirrhosis-re-
lated mobile telehealth application, which is a critical step on the 
pathway to ultimate usage.
4.3 | The impact of informal caregivers
The presence of an informal caregiver was significantly associated 
with all TAM domains (perceived usefulness, perceived ease of use, 
computer anxiety, behavioural intent), and greatly influenced a pa-
tient's overall decision to download the EncephalApp©. The shared 
psychological, financial and quality-of-life disease burden seen in 
patients with cirrhosis and their caregivers may partly explain this 
finding.34-36 It is conceivable that patients with informal caregivers 
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saw a perceived usefulness that extended beyond themselves and 
encompassed their caregiver. In fact, if an individual believes that 
someone close to them thinks that he/she should use the technol-
ogy, then the individual's perceived usefulness of the technology is 
significantly increased.17 We also saw significantly less computer 
anxiety and more perceived ease of use scores in participants with 
informal caregivers. We postulate that perhaps the technological 
help participants believed an informal caregiver could provide in-
creased their comfort with technology use. Our study did not ex-
plicitly involve caregivers but given low after-visit utilization, future 
interventions should incorporate caregivers to reinforce the use of 
remote monitoring technology.
4.4 | Barriers to Encephalapp© use
While we were able to identify elements that increased a patient's 
acceptance and willingness to download a smartphone application 
for cirrhosis care, actual usage was modest (32%) and the small 
sample size likely precluded an analysis of predictors of use. More 
broadly, the per cent of patients who used the application from the 
overall patient population was only 14%. This highlights the multiple 
barriers to technology use in cirrhosis that must be considered in 
leveraging technology to improve cirrhosis care. First, technology-
related barriers – no smartphone, difficulty accessing the Internet in 
clinic, unknown application store information and inadequate phone 
storage – accounted for a 32% decrease in the number of patients 
who could download the application. Second, even after successful 
installation, personal factors, such as forgetfulness and interven-
ing hospitalizations, precluded use of the EncephalApp©. Certainly, 
future implementations of smartphone applications should include 
telephone follow-up to reiterate instructions on its use, reminders 
for use and potentially a help-line.
4.5 | Contextual factors/limitations
Our data must be interpreted within the context of the study design. 
First, survey responses were based on opinions about the imaginary 
Cirrhosis Health Application, but analysis of the decision to down-
load an application was determined based on the EncephalApp©. 
Despite this, results remained consistent with higher behavioural 
intent to use the Cirrhosis Health Application (which included a psy-
chometric component) being associated with a higher likelihood of 
downloading the EncephalApp©. Second, in informing patients that 
the results obtained from the EncephalApp© would not be used to 
guide their management, perceived usefulness was effectively re-
duced. Notably, in spite of this information, 71% of eligible partici-
pants still expressed willingness to download the application. Third, 
the EncephalApp© was created as a point-of-care test for detecting 
minimal hepatic encephalopathy in the clinical setting.25 However, 
in-home use of the EncephalApp© has been shown to be feasi-
ble and effective for detecting cognitive changes in persons with 
cirrhosis.14 Fourth, the study population had a relatively low me-
dian MELD-Na and was likely more clinically stable than a sample of 
transplant waitlisted patients. However, interventions, such as mo-
bile applications, are likely best deployed at a stage where success-
ful intervention can prevent hospitalization.8 Given the high rate of 
prior decompensation in our sample, this represents an ideal study 
population where the risk of future events is high but there is likely 
an important decompensation-free interval where individuals have 
time to use and become acclimated to these novel interventions. 
Lastly, in practice, various members of a care team would approach 
patients about downloading a novel smartphone technology. In the 
current study, the same individual recruited all participants so as to 
not introduce differences in recruiters as a confounding variable.
5  | CONCLUSION
In cirrhosis, overall patient acceptance of a hypothetical cirrhosis-
related smartphone application is high; though multiple barriers 
exist that limit actual usage. Those most agreeable to adopt these 
technologies can be identified based on available clinical factors and 
principles from the technology acceptance model. Perceived use-
fulness, perceived ease of use and computer anxiety, as well as the 
disease stage and the presence of an informal caregiver, should be 
of paramount importance in the successful development and imple-
mentation of mobile technologies to improve cirrhosis care.
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